13F filer · CIK 314957 ↗
University of Chicago
You are looking at Q2 2024. See the latest, Q2 2026 →
Reported value
$129.7M
+87% on the quarter before
Positions
7
1 new · 1 sold out
Top 10
100.0%
of the value
Est. gain
−$385,719
on stocks held all quarter
Est. return
−0.6%
on those stocks since Q1 2024
Positions as of Jun 30, 2024, from University of Chicago's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2024. Striped tiles are options.
Largest buys
Since Q1 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Vanguard Intl Equity Index F~$30.9MAdded · 9.7% → 29.1%+274,652 shares
- Vanguard Index Fds~$26.2MAdded · 11.3% → 26.5%+52,143 shares
- Vanguard Bd Index Fds Total Bnd Mrkt~$2.7MAdded · 76.4% → 42.6%+37,775 shares
- Abbvie Inc Com~$1.0MNew · 0.0% → 0.8%+6,000 shares
Largest sells
Since Q1 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Adtalem Global Ed Inc~$53,456Sold out · 0.1% → 0.0%−1,040 shares
Holdings
As of Jun 30, 2024. Changes are in shares against Mar 31, 2024, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanguard Bd Index Fds Total Bnd MrktTOTAL BND MRKT · shares +5.2% · price −0.8% | 42.6% | $55.2M | −$422,813 | ||||||||
| Vanguard Intl Equity Index FTT WRLD ST ETF · shares +452% · price +1.9% | 29.1% | $37.8M | +$129,544 | ||||||||
| Vanguard Index FdsS&P 500 ETF SHS · shares +320% · price +4.4% | 26.5% | $34.3M | +$345,144 | ||||||||
| Abbvie Inc ComCOM · shares New | 0.79% | $1.0M | — | ||||||||
| Nkgen Biotech IncCOM · shares 0% · price −32.8% | 0.54% | $698,500 | −$341,000 | ||||||||
| Ovintiv IncCOM · shares 0% · price −9.7% | 0.36% | $468,700 | −$50,300 | ||||||||
| Pyxis Oncology IncCOMMON STOCK · shares 0% · price −22.3% | 0.12% | $161,300 | −$46,294 | ||||||||
| Total · 7 positions | 100% | $129.7M | −$385,719 |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2024 to Q2 2024: 6 stocks held throughout, down $385,719 (−0.6%).
- Vanguard Index Fds+$345,144+4%
- Vanguard Intl Equity Index F+$129,544+2%
- Pyxis Oncology Inc−$46,294−22%
- Ovintiv Inc−$50,300−10%
- Nkgen Biotech Inc−$341,000−33%
- Vanguard Bd Index Fds Total Bnd Mrkt−$422,813−1%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $419.7M+30% | SEC ↗ |
| Q1 2026 | May 7, 2026 | $323.4M+56% | SEC ↗ |
| Q4 2025 | Feb 6, 2026 | $206.8M+1% | SEC ↗ |
| Q3 2025 | Nov 6, 2025 | $204.6M+74% | SEC ↗ |
| Q2 2025 | Aug 7, 2025 | $117.5M+78% | SEC ↗ |
| Q1 2025 | May 8, 2025 | $66.0M−38% | SEC ↗ |
| Q4 2024 | Feb 5, 2025 | $106.5M−10% | SEC ↗ |
| Q3 2024 | Oct 16, 2024 | $118.3M−9% | SEC ↗ |
| Q2 2024 | Jul 15, 2024 | $129.7M+87% | SEC ↗ |
| Q1 2024 | Apr 15, 2024 | $69.3M−4% | SEC ↗ |
| Q4 2023 | Mar 14, 2024 | $72.0M−53% | SEC ↗ |
| Q3 2023 | Mar 14, 2024 | $151.8M−31% | SEC ↗ |
| Q2 2023 | Mar 14, 2024 | $219.4M−0% | SEC ↗ |
| Q1 2023 | Mar 14, 2024 | $219.7M+69% | SEC ↗ |
| Q4 2022 | Mar 14, 2024 | $130.1M+97% | SEC ↗ |
| Q3 2021 | Mar 14, 2024 | $66.1M+4% | SEC ↗ |
| Q2 2021 | Mar 14, 2024 | $63.4M+22% | SEC ↗ |
| Q1 2021 | Mar 14, 2024 | $52.1M+13% | SEC ↗ |
| Q4 2020 | Mar 14, 2024 | $46.2M+302% | SEC ↗ |
| Q3 2020 | Oct 15, 2020 | $11.5M−6% | SEC ↗ |
| Q2 2020 | Jul 15, 2020 | $12.3M+36% | SEC ↗ |
| Q1 2020 | Apr 24, 2020 | $9.0M−74% | SEC ↗ |
| Q4 2019 | Feb 20, 2020 | $34.7M−63% | SEC ↗ |
| Q3 2019 | Oct 24, 2019 | $94.1M−9% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $103.6M+2% | SEC ↗ |
| Q1 2019 | May 6, 2019 | $101.4M−38% | SEC ↗ |
| Q4 2018 | Feb 12, 2019 | $164.0M−14% | SEC ↗ |
| Q3 2018 | Nov 13, 2018 | $189.9M−11% | SEC ↗ |
| Q2 2018 | Aug 8, 2018 | $213.4M−45% | SEC ↗ |
| Q1 2018 | Apr 11, 2018 | $388.1M | SEC ↗ |